BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Wang QQ, Zhou YC, Zhou Ge YJ, Qin G, Yin TF, Zhao DY, Tan C, Yao SK. Comprehensive proteomic signature and identification of CDKN2A as a promising prognostic biomarker and therapeutic target of colorectal cancer. World J Clin Cases 2022; 10(22): 7686-7697 [PMID: 36158487 DOI: 10.12998/wjcc.v10.i22.7686]
URL: https://www.wjgnet.com/1007-9327/full/v10/i22/7686.htm
Number Citing Articles
1
R. Sachin Sriram, P. Anitha, K. Balachander, P. Chandra, A. Paramasivam, J. Vijayashree Priyadharsini. Genetic alterations in CDKN2A interacting network and their putative association with head and neck squamous cell carcinomaHuman Gene 2024; 40: 201276 doi: 10.1016/j.humgen.2024.201276
2
Han Chen, Jiao Deng, Tie-Wei Hou, Yong-Qi Shan. Villosol reverses 5-FU resistance in colorectal cancer by inhibiting the CDKN2A gene regulated TP53-PI3K/Akt signaling axisJournal of Ethnopharmacology 2024; 325: 117907 doi: 10.1016/j.jep.2024.117907
3
Vlad Alexandru Ionescu, Gina Gheorghe, Nicolae Bacalbasa, Alexandru Laurentiu Chiotoroiu, Camelia Diaconu. Colorectal Cancer: From Risk Factors to OncogenesisMedicina 2023; 59(9): 1646 doi: 10.3390/medicina59091646
4
Di Zhang, Tao Wang, Yi Zhou, Xipeng Zhang. Comprehensive analyses of cuproptosis-related gene CDKN2A on prognosis and immunologic therapy in human tumorsMedicine 2023; 102(14): e33468 doi: 10.1097/MD.0000000000033468
5
Khalid Saad Alharbi. The ncRNA-TGF-β axis: Unveiling new frontiers in colorectal cancer researchPathology - Research and Practice 2024; 254: 155138 doi: 10.1016/j.prp.2024.155138